Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ruboxistaurin mesylate monohydrate is a PKC beta inhibitor potentially for the treatment of diabetic nephropathy and diabetic macular edema. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約10-14 週間 | ¥ 590,000 |
50 mg | 約10-14 週間 | ¥ 776,000 |
100 mg | 約10-14 週間 | ¥ 1,056,000 |
説明 | Ruboxistaurin mesylate monohydrate is a PKC beta inhibitor potentially for the treatment of diabetic nephropathy and diabetic macular edema. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt. |
分子量 | 582.67 |
分子式 | C29H34N4O7S |
CAS No. | 202260-21-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ruboxistaurin mesylate monohydrate 202260-21-7 Ruboxistaurin mesylate Monohydrate Difenamizole hydrochloride Ruboxistaurin Mesylate Inhibitor inhibitor inhibit